Skip to main
  1. Stocks
  2. Evommune Inc
  3. Forecast
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is attractive fundamentally because it combines a relatively modest ~$290MM market cap with a pro-forma cash balance of about $290MM, giving it runway into 2H29 and reducing near-term financing risk. The company’s pipeline also has multiple shots on goal, led by EVO301, which showed promising Phase 2a proof-of-concept in atopic dermatitis and is advancing to a Phase 2b dose-ranging trial in mid-2027, while additional studies in ulcerative colitis and other inflammatory settings expand its addressable opportunity. Further upside comes from EVO570’s in-licensed, highly differentiated oral VAV1 degrader profile—sub-nanomolar potency, high selectivity, durable degradation, and QD dosing potential—which supports a credible path to meaningful value creation across 2027 clinical catalysts.

Bears say

Evommune is increasingly a single-asset story after EVO756 failed to show differentiation from placebo in phase 2b CSU and AD, with no meaningful efficacy signal on itch or EASI and the program now assigned no value by the cited analysis. The company has no marketed products, faces substantial regulatory and execution risk, and must still prove EVO301 in ulcerative colitis and other settings despite a cash-adjusted enterprise value of about $185 million and cash runway only extending into 2029. With escalating R&D spending, no demonstrated subcutaneous translation for IL-18, and a highly competitive AD landscape, the business remains vulnerable to further downside if future data fail to produce clear efficacy, safety, or commercialization advantages.

Evommune Inc (EVMN) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Evommune Inc (EVMN) Analyst Forecast & Price Prediction

Get the latest Evommune Inc (EVMN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evommune Inc (EVMN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 10 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Evommune Inc (EVMN) Analyst Forecast & Price Prediction

Get the latest Evommune Inc (EVMN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evommune Inc (EVMN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EVMN stock data and trends